Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Tuesday 21 February, 2017

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 4792X
GlaxoSmithKline PLC
21 February 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

67,867 (Deferred)

 

 

£0.0000

22,621 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

90,448

£0.0000

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.3353

31,898 (Deferred)

 

 

£16.3353

10,633 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

42,531

£16.3353

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

14,860 (Deferred)

 

 

£0.0000

4,954 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

19,814

£0.0000

e)

Date of the transaction

2017-02-21

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.3500

6,986 (Deferred)

 

 

£16.3500

2,330 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

9,316

£16.3500

e)

Date of the transaction

2017-02-21

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

12,115 (Deferred)

 

 

£0.0000

4,039 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

16,154

£0.0000

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.3425

5,809 (Deferred)

 

 

£16.3450

1,937 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

7,746

£16.3431

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

7,517 (Deferred)

 

 

£0.0000

2,506 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

10,023

£0.0000

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.3700

3,604 (Deferred)

 

 

£16.3550

1,202 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

4,806

£16.3662

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

SVP, Communications & Government Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.0000

4,528 (Deferred)

 

 

£0.0000

1,509 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

6,037

£0.0000

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

SVP, Communications & Government Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.3450

2,171 (Deferred)

 

 

£16.3500

724 (Matching)

 

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

2,895

£16.3462

e)

Date of the transaction

2017-02-20

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHDFLFLDLFFBBL

a d v e r t i s e m e n t